Samarth Kulkarni Sells 19,582 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the sale, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Samarth Kulkarni also recently made the following trade(s):

• On Friday, March 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $72.48, for a total transaction of $1,449,600.00.
• On Monday, March 11th, Samarth Kulkarni sold 9,802 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $78.26, for a total transaction of $767,104.52.
• On Tuesday, February 20th, Samarth Kulkarni sold 6,370 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $79.67, for a total transaction of $507,497.90.
• On Thursday, February 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $80.36, for a total transaction of $1,607,200.00.
• On Monday, January 29th, Samarth Kulkarni sold 50,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.51, for a total transaction of $3,025,500.00.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $55.56 on Thursday. The firm has a 50-day moving average of $73.51 and a 200-day moving average of $63.34. The stock has a market cap of $4.72 billion, a PE ratio of -28.35 and a beta of 1.76. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million for the quarter, compared to analyst estimates of $148.72 million. During the same quarter in the prior year, the business posted ($1.41) EPS. The business’s quarterly revenue was up 3253.3% compared to the same quarter last year. As a group, analysts predict that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the business. Blue Trust Inc. bought a new position in CRISPR Therapeutics during the fourth quarter worth about $32,000. Bourgeon Capital Management LLC increased its position in CRISPR Therapeutics by 1,000.0% during the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares during the period. Main Street Group LTD bought a new position in CRISPR Therapeutics during the fourth quarter worth about $34,000. CWM LLC increased its position in CRISPR Therapeutics by 80.7% during the third quarter. CWM LLC now owns 582 shares of the company’s stock worth $26,000 after acquiring an additional 260 shares during the period. Finally, NBC Securities Inc. increased its position in CRISPR Therapeutics by 257.6% during the first quarter. NBC Securities Inc. now owns 608 shares of the company’s stock worth $41,000 after acquiring an additional 438 shares during the period. 69.20% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CRSP has been the subject of a number of analyst reports. Chardan Capital raised their target price on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. Royal Bank of Canada raised their target price on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research report on Thursday, February 22nd. Wells Fargo & Company increased their price target on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, February 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, April 11th. Finally, Morgan Stanley increased their price target on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a research note on Monday, February 26th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $74.93.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.